News & Events

• June 7, 2023
  

  Newcastle University’s John Walton Muscular Dystrophy Research Centre Contributes Data to C-Path’s RDCA-DAP

  C-Path announced today that Newcastle University UK’s John Walton Muscular Dystrophy Research Centre will contribute data to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) managed by C-Path. These data come from the Myotubular (MTM) and Centronuclear Myopathy (CNM) Patient Registry and the Global Registry for COL6-related dystrophies.

• June 6, 2023
  

  Shaping the Global Innovation and Access Landscape for Better Paediatric Medicines: C-Path Becomes Official Partner of WHO

  Critical Path Institute (C-Path), a leading global nonprofit committed to expediting drug development through the acceleration of regulatory-endorsed solutions, today announced an official partnership with the World Health Organization’s (WHO) Global Accelerator for Paediatric Formulations (GAP-f) project.

• May 31, 2023
  

  CACNA1A Foundation to Contribute Data to C-Path’s RDCA-DAP, Accelerating Neurological Disease Research and Therapeutic Development

  TUCSON, Ariz., May 31, 2023 — Critical Path Institute (C-Path) announced today that the CACNA1A Foundation, a parent-led nonprofit organization dedicated to creating awareness and finding a cure for CACNA1A-genetic related disorders, will be contributing data to the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) managed by C-Path. CACNA1A is a gene that is...
• May 31, 2023
  

  C-Path’s Transplant Therapeutics Consortium’s Work Highlighted in Recent Publication in the American Journal of Transplantation

  C-Path’s Transplant Therapeutics Consortium is pleased to announce the recent publication in the American Journal of Transplantation by Klemens Budde and Bruce Kaplan, “Stronger together: lessons from the iBox qualification process.” The article highlights TTC’s work as the only community-based public-private partnership focused on reinvigorating drug development in transplantation.   As the manuscript states, “The close collaboration...
• May 25, 2023
  

  C-Path Welcomes Red Nucleus Clinical

  C-Path is proud to welcome Red Nucleus Clinical as the newest member of its Electronic Clinical Outcome Assessment (eCOA) Consortium. Comprised of 22 firms that provide electronic data collection technologies and services for capturing patient-reported outcome and other clinical outcome assessment data in clinical trials, eCOA Consortium members collaborate in a pre-competitive environment to support and conduct...